News

The phase 1/2 MARINA trial assessed the activity of AOC 1001 across key biomarkers, including spliceopathy, an important biomarker for myotonic dystrophy type 1, and knockdown of DMPK mRNA.

Neurology News Network for the week ending May 20, 2023. [WATCH TIME: 4 minutes]

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending May 19, 2023.

The assistant professor of neurology at the University of North Carolina at Chapel Hill discussed the importance of recognizing disability as part of diversity in neurology, emphasizing the need for inclusive communication and accessibility for disabled patients. [WATCH TIME: 10 minutes]

Treatment with valbenazine at doses of up to 80 mg once per day significantly improved chorea, as demonstrated by the mean change in UHDRS Total Maximal Chorea scores.

The associate professor of neurology at Albert Einstein College of Medicine talked about a review on neonatal seizures recently published in the New England Journal of Medicine. [WATCH TIME: 5 minutes]

Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with James Berry, MD, PhD. [LISTEN TIME: 14 minutes]

Anand Patel, MD, CPI, chief medical officer at Conquest Research, discussed a phase 2 study that investigated the efficacy and safety of LX9211, an oral medication targeting neuropathic pain.

Neurological rehabilitation, or neurorehabilitation, can be described as the use of rehabilitation interventions to improve or maintain function and quality of life in the context of neurological conditions.

AUPN Leading Edge Episode 6 features John D. England, MD, FAAN, and Jinsy Andrews, MD, MSc, who discuss the experiences, opportunities, and challenges while transitioning between academia and industry. [LISTEN TIME: 33 minutes]

The associate professor at the University of Colorado talked about a study involving pediatric patients with multiple sclerosis and related disorders, and the risk of COVID-19 infection among those on B-cell-depleting therapy. [WATCH TIME: 5 minutes]

Poststroke patients with more severe deficits and better clinical factors received larger doses of rehabilitation therapy, according to a recently published study.

Over a 4-month treatment period, the agent was well tolerated, with patients showing no significant changes in ADAS-Cog or CDR-SB scores, indicating no cognitive decline.

Comprised of the recharge-free Proclaim SCS family and the rechargeable Eterna SCS platform, the approval for Abbott’s spinal cord stimulation system was backed by the large-scale, DISTINCT study.

The neurology PGY-3 at Mayo Clinic in Arizona talked about findings from a retrospective cohort study that examined blood pressure in patients who were prescribed a migraine medication. [WATCH TIME: 6 minutes]

Findings from the 12-week study showed a significant decrease in total number of new gadolinium-enhancing lesions in patients with relapsing MS on fenebrutinib relative to placebo.

Following thymectomy, more than 80% of patients with myasthenia gravis showed symptom improvement, as demonstrated by changes in Myasthenia Gravis Foundation of America scores.

The associate professor of neurology at the Cleveland Clinic Lerner College of Medicine provided insight on the necessary research needed to understand why certain races experience more significant multiple sclerosis disease progress. [WATCH TIME: 4 minutes]

The director of the Sleep Disorders Center and staff in the Epilepsy Center at Cleveland Clinic provided perspective on the current state of sleep and epilepsy research, including the role of postical generalized EEG suppression as a biomarker for SUDEP.

Marcelo Bigal, MD, PhD, chief executive officer of Ventus Therapeutics, talked about the relationship between inflammation and neurodegeneration in Parkinson disease, and the importance of targeting NLRP3.

Improvements seen in patients with CDD during the 12-week maintenance period of the study were similar to that observed in a recent trial of ganaxolone, the first FDA-approved therapy for CDD.

At the 2023 AAN Annual Meeting, the neuromuscular disease specialist and professor of neurology at the University of Kansas Medical Center talked about the phase 3 study investigating ataluren for Duchenne muscular dystrophy. [WATCH TIME: 5 minutes]

Differences in personal experience of dyskinesias in Parkinson disease were observed across multiple cultures, which could be attributable to intrinsic cultural peculiarities.

The director of the Mayo Clinic Center for Multiple Sclerosis and Autoimmune Neurology discussed findings from the phase 3 CHAMPION-NMOSD trial of ravulizumab in patients with neuromyelitis optica spectrum disorder. [WATCH TIME: 5 minutes]

Regardless of highly different demographics and smaller sample size, the association between amyloid in the brain and plasma was influenced by overall vascular risk score, and was only consistently observed in APOE ɛ4 carriers.

Timothy A. Leichliter, MD, a neurologist at Allegheny Health Network, provided context on the institution’s boxing program for Parkinson disease, and the need for patients to remain active.

At the 2023 AAN Annual Meeting, the professor of neurology at the Geisel School of Medicine at Dartmouth talked about the effectiveness of a remote electrical neuromodulation device that offers potential relief for both episodic and chronic migraine. [WATCH TIME: 3 minutes]

Leo H. Wang, MD, PhD, FAAN, associate professor of neurology, University of Washington Medical Center, talked about the phase 2 study of losmapimod for facioscapulohumeral muscular dystrophy presented at the 2023 AAN Annual Meeting.